Follow The Filings

Johnson & Johnson

New Brunswick, NJ 7 processed 13Fs on this site, 2025 Q3 to 2026 Q3

  • $762M
  • 15 holdings
  • 2026 Q3
  • −4.6% QoQ
  • Top 5 89.3%

In 2026 Q3 Johnson & Johnson added to Cerebras Systems.

Portfolio

2026 Q3, filed 10/26/2026, top 12 of 15 holdings

Top 5 89.3%, top 10 98.8%

  1. PTGX, Protagonist Therapeutics 45.3%
  2. NBTX, Nanobiotix 23.0%
  3. MGTX, Meiragtx 9.6%
  4. RAPP, Rapport Therapeutics 7.9%
  5. CTNM, Contineum Therapeutics 3.5%
  6. CBRS, Cerebras Systems 3.0%
  7. Xencor 2.4%
  8. Legend Biotech 2.1%
  9. FATE, Fate Therapeutics 1.1%
  10. CVRX 0.9%
  11. PRCT, Procept Biorobotics 0.9%
  12. NMRA, Neumora Therapeutics 0.1%
  13. Other 0.2%

AUM over time

2026 Q3 $762M −4.6% QoQ
2025 Q3: $504M 2025 Q3: $504M
Q3 2025
2025 Q4: $555M, +10.1% QoQ 2025 Q4: $555M, +10.1% QoQ
Q4
2026 Q1: $652M, +17.5% QoQ 2026 Q1: $652M, +17.5% QoQ
Q1 2026
2026 Q2: $799M, +22.5% QoQ 2026 Q2: $799M, +22.5% QoQ
Q2
2026 Q3: $762M, −4.6% QoQ 2026 Q3: $762M, −4.6% QoQ
Q3

Latest book

2026 Q3 2026 Q2, filed 11d ago, long equity only

Download CSV Download Excel All activity
PTGX, Protagonist Therapeutics 45.30% Hold 2,449,183 $140.89 $345M — —
NBTX, Nanobiotix 23.01% Hold 5,623,816 $31.16 $175M — —
MGTX, Meiragtx 9.59% Hold 6,641,064 $11.00 $73M — —
RAPP, Rapport Therapeutics 7.87% Hold 1,784,517 $33.60 $60M — —
CTNM, Contineum Therapeutics 3.49% Hold 1,979,173 $13.42 $27M — —
CBRS, Cerebras Systems 3.00%, was 1.48% Add +140.1% 128,649 $177.65 $23M +75,063 +$11M
Xencor 2.45% Hold 748,062 $24.95 $19M — —
Legend Biotech 2.13% Hold 814,586 $19.89 $16M — —
FATE, Fate Therapeutics 1.05% Hold 3,379,064 $2.37 $8M — —
CVRX 0.92% Hold 4,024,861 $1.75 $7M — —
PRCT, Procept Biorobotics 0.86% Hold 357,939 $18.22 $6.5M — —
NMRA, Neumora Therapeutics 0.14% Hold 1,849,445 $0.5962 $1.1M — —
Vor Biopharma 0.13% Hold 53,732 $19.08 $1M — —
LAB, Standard Biotools 0.03% Hold 311,967 $0.7406 $231K — —
ACET, Adicet Bio 0.02% Hold 22,779 $7.14 $163K — —

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2026 Q2. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top.

Filings history

5 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q3 15 $762M −4.6% 13F-HR 10/26/2026 000090445426000541
2026 Q2 15 $799M +22.5% 13F-HR 8/6/2026 000090445426000435
2026 Q1 16 $652M +17.5% 13F-HR 5/13/2026 000090445426000280
2025 Q4 17 $555M — RESTATEMENT 3/18/2026 000090445426000192
2025 Q4 17 $555M +10.1% 13F-HR 2/13/2026 000090445426000111
2025 Q3 20 $504M — RESTATEMENT 3/18/2026 000090445426000190
2025 Q3 20 $504M — 13F-HR 11/13/2025 000090445425000587

About

Johnson & Johnson

7 processed 13Fs on this site, 2025 Q3 to 2026 Q3

SEC filing name
JOHNSON & JOHNSON
Location
New Brunswick, NJ
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf